Pharis Mohideen
Chief Tech/Sci/R&D Officer bei DBV TECHNOLOGIES
Vermögen: 118 152 $ am 31.03.2024
Profil
Pharis Mohideen currently works at DBV Technologies SA, as Chief Medical Officer from 2019.
Dr. Mohideen also formerly worked at Novartis International AG, as Senior Director from 2006 to 2008, Bristol Myers Squibb Co., as Principal, Novartis Oncology, Inc., as Global Head-Clinical Program from 2008 to 2012, Millendo Therapeutics US, Inc., as Chief Medical Officer, the University of Hawai'i at Hilo, as Assistant Professor-Medicine, Shionogi, Inc., as Vice President-Clinical Development from 2012 to 2014, and Millendo Therapeutics, Inc., as Chief Medical Officer from 2014 to 2019.
Dr. Mohideen received his graduate degree from Vanderbilt University and undergraduate degree, graduate degree, and doctorate degree from the University of Hawai'i at Hilo.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
DBV TECHNOLOGIES SA
0,09% | 22.11.2023 | 82 194 ( 0,09% ) | 118 152 $ | 31.03.2024 |
Aktive Positionen von Pharis Mohideen
| Unternehmen | Position | Beginn |
|---|---|---|
| DBV TECHNOLOGIES | Chief Tech/Sci/R&D Officer | 22.07.2019 |
Ehemalige bekannte Positionen von Pharis Mohideen
| Unternehmen | Position | Ende |
|---|---|---|
| MILLENDO THERAPEUTICS | Chief Tech/Sci/R&D Officer | 12.07.2019 |
Shionogi, Inc.
 Shionogi, Inc. Pharmaceuticals: MajorHealth Technology Part of Shionogi & Co., Ltd., Shionogi, Inc. is a pharmaceutical company based in Florham Park, NJ. Since 1878, the private company has been utilizing science to address health challenges and has discovered several novel antibiotics and medications for HIV and influenza. Shionogi conducts ongoing research into established products and new antibiotic compounds, as well as developing an investigational antiviral for COVID-19. The company is committed to pursuing discovery through partnerships, including collaboration with scientists through investigator-initiated research. Shionogi is dedicated to advancing the greater good by developing, partnering, and commercializing medicine to treat serious unmet medical needs in infectious disease and other areas of high medical need including neurology and cardiovascular disease. Nathan McCutcheon has been the CEO of the company since 2019. | Corporate Officer/Principal | 01.10.2014 |
Novartis Oncology, Inc.
 Novartis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Novartis Oncology, Inc. provides healthcare solutions. The firm offers medicines, eye care and generic pharmaceuticals. It also offers patient declaration, patient support and assistance, and additional resources. The company is headquartered in East Hanover, NJ. | Corporate Officer/Principal | 01.01.2012 |
Novartis International AG
 Novartis International AG Pharmaceuticals: MajorHealth Technology Novartis International AG manages the Novartis Group. It provides administrative, financial, legal, and technical services. It also offers scientific consultation to the Group. The company was founded on December 13, 1989 and is headquartered in Basel, Switzerland. | Corporate Officer/Principal | 01.01.2008 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
Ausbildung von Pharis Mohideen
| Vanderbilt University | Graduate Degree |
| University of Hawai'i at Hilo | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| DBV TECHNOLOGIES | Health Technology |
| Private Unternehmen | 5 |
|---|---|
Novartis International AG
Novartis International AG Pharmaceuticals: MajorHealth Technology Novartis International AG manages the Novartis Group. It provides administrative, financial, legal, and technical services. It also offers scientific consultation to the Group. The company was founded on December 13, 1989 and is headquartered in Basel, Switzerland. | Health Technology |
Novartis Oncology, Inc.
Novartis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Novartis Oncology, Inc. provides healthcare solutions. The firm offers medicines, eye care and generic pharmaceuticals. It also offers patient declaration, patient support and assistance, and additional resources. The company is headquartered in East Hanover, NJ. | Health Technology |
Millendo Therapeutics US, Inc.
 Millendo Therapeutics US, Inc. Pharmaceuticals: MajorHealth Technology Millendo Therapeutics US, Inc. engages in the development of novel treatment for adrenal cancer. It focuses on developing a portfolio of disease-modifying treatments for endocrine disorders caused by hormone dysregulation. The company was founded by Raili E. Kerppola, Julia C. Owens, and Gary D. Hammer in January 2012 and is headquartered in Ann Arbor, MI. | Health Technology |
Shionogi, Inc.
Shionogi, Inc. Pharmaceuticals: MajorHealth Technology Part of Shionogi & Co., Ltd., Shionogi, Inc. is a pharmaceutical company based in Florham Park, NJ. Since 1878, the private company has been utilizing science to address health challenges and has discovered several novel antibiotics and medications for HIV and influenza. Shionogi conducts ongoing research into established products and new antibiotic compounds, as well as developing an investigational antiviral for COVID-19. The company is committed to pursuing discovery through partnerships, including collaboration with scientists through investigator-initiated research. Shionogi is dedicated to advancing the greater good by developing, partnering, and commercializing medicine to treat serious unmet medical needs in infectious disease and other areas of high medical need including neurology and cardiovascular disease. Nathan McCutcheon has been the CEO of the company since 2019. | Health Technology |
Millendo Therapeutics, Inc.
 Millendo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Millendo Therapeutics, Inc. is a biopharmaceutical company, which engages in seeking distinct and transformative treatments where there is a significant unmet medical need. The company was founded by Julia C. Owens in January 2012 and is headquartered in Ann Arbor, MI. | Health Technology |
